Should older adults be screened for dementia?

J. Wesson Ashford, Soo Borson, Ruth O'Hara, Paul Dash, Lori Frank, Philippe Robert, William R. Shankle, Mary C. Tierney, Henry Brodaty, Frederick A. Schmitt, Helena C. Kraemer, Herman Buschke

Research output: Contribution to journalArticlepeer-review

54 Scopus citations

Abstract

The question of whether to screen for dementia and Alzheimer's disease (AD) has been discussed in many forums throughout the world. Generally, medical advisory groups and policy-making groups have recognized the importance of early diagnosis but have uniformly avoided making recommendations to screen at-risk populations. This presentation reflects the support for reconsidering the importance of screening individuals at risk or above a certain age. In this statement, the majority of the authors support the consideration of dementia risk factors in individuals at age 50, with routine yearly screening after 75. Other authors remain concerned that the benefits of treatments of early disease do not yet support a general screening recommendation. These statements are made to encourage progress toward the development of a consensus regarding the widespread institution of screening policy. Accordingly, members of the worldwide scientific community are invited to add their perspective by contributing short commentaries (1500 words) on this subject.

Original languageEnglish (US)
Pages (from-to)76-85
Number of pages10
JournalAlzheimer's and Dementia
Volume2
Issue number2
DOIs
StatePublished - Apr 2006

Bibliographical note

Funding Information:
Drs Ashford, O’Hara, and Kraemer are supported by grant P30 AG 17824 from the National Institutes of Health, by the Medical Research Service of the Veterans Affairs Palo Alto Health Care System, and by the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). Dr O’Hara is also supported by NIH grants AG18784 and MH070886. Dr Borson is supported by National Institute on Aging Grants P50 AG05136 and R01 AG025515. Dr Buschke is supported by National Institute on Aging Grant AG03949, NICHD grant HD-01799. Dr Schmitt is supported by National Institute on Aging grants P50 AG05144 and PO1 AG19241. Dr. Shankle is a Research Fellow, Cognitive Sciences, U. C. Irvine. Dr Brodaty has been advisor to Pfizer, Novartis, Janssen, Lundbeck, and AstraZenica and has received investigator-initiated research funding from Pfizer and Janssen Pharmaceutica.

Funding Information:
All of the authors have been associated with the development of screening tools for dementia and Alzheimer’s disease. Dr Ashford is on the Speaker’s Bureau for Janssen / Ortho-McNeil Pharmaceuticals. Dr Borson is a member of the Speaker’s Bureau for Pfizer Pharmaceuticals, Forest Laboratories, and Novartis and has received investigator-initiated research funding from Pfizer, Forest, and Janssen Pharmaceutica and a conference grant from Eisai. Dr. Shankle is on the speaker’s bureaus for Novartis and Ortho-McNeil Pharmaceuticals, and is currently chief medical officer of Medical Care Corporation.

Keywords

  • Alzheimer's disease
  • Case-finding
  • Dementia
  • Diagnosis
  • Mild cognitive impairment
  • Screening

Fingerprint

Dive into the research topics of 'Should older adults be screened for dementia?'. Together they form a unique fingerprint.

Cite this